Personalized Medicine for Classical Anesthesia Drugs and Cancer Progression

Costa, Bárbara; Mourão, Joana; Vale, Nuno

doi:10.3390/jpm12111846

Cited by 4 publications

(3 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to other preanesthetic drugs, the use of scopolamine efectively reduces the dosage of anesthetic agents and, consequently, lowers the occurrence of postoperative adverse reactions. Multiple studies have suggested that perioperative anesthesia drugs can have an impact on the viability of tumor cells and signifcantly infuence patient prognosis [44,45]. In the prescreening drug experiment, this study discovered that scopolamine may possess the capability to inhibit the metastasis of tumor cells.…”

Section: Discussionmentioning

confidence: 92%

The Mechanism of Scopolamine’s Effect on Migration Function of Lung Cancer Cells: A Network Pharmacology and Bioinformatics Perspective

Xiao,

Ma,

et al. 2024

International Journal of Clinical Practice

View full text Add to dashboard Cite

Background. This study utilized network pharmacology and bioinformatics analysis to identify the hub genes influenced by scopolamine in lung cancer. Methods. The effect of scopolamine on lung cancer was investigated by cell invasion assay and cell scratch assay. The analysis involved protein-protein interaction (PPI) networks topology analysis to identify these genes, and subsequent differential analysis and survival analysis were conducted using gene expression profile interaction analysis (GEPIA). Furthermore, the findings were supported by molecular docking experiments for verification. Results. Results from cell invasion and scratch assays suggest that scopolamine inhibits the migration of lung cancer cells. JAK2, JAK3, CCR5, and ACE were identified as the top four hub genes that have an impact on lung cancer. KEGG enrichment analysis revealed that the scopolamine response in lung cancer is significantly associated with ten pathways, including “neuroactive ligand-receptor interaction in cancer,” “PD-1 checkpoint pathway in cancer,” “chemokine signaling pathway,” “PD-L1 expression,” and others. Additionally, the expression levels of JAK2, JAK3, CCR5, and ACE were found to be correlated with survival in patients with lung cancer. Furthermore, molecular docking experiments demonstrated that scopolamine binds and forms stable complexes with the protein products of all four aforementioned genes. The main targets of scopolamine in the treatment of lung cancer are JAK2, JAK3, CCR5, and ACE. Conclusion. Scopolamine has a significant effect on various cellular functions in lung cancer cells, potentially reducing the likelihood of metastasis. Based on these findings, it is recommended to consider administering scopolamine as part of the preoperative phase for patients with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 92%

The Mechanism of Scopolamine’s Effect on Migration Function of Lung Cancer Cells: A Network Pharmacology and Bioinformatics Perspective

Xiao,

Ma,

et al. 2024

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Te rocuronium-induced neuromuscular blockade efect is similarly prolonged during liver resection in patients with hepatocellular carcinoma without preoperative hepatic impairment, but sugammadex reversal is efective [10]. Sugammadex, a potent antagonist of rocuronium bromide, is thought to promote recovery after surgery in cancer patients, but its efect on cancer cells has not been reported in studies, possibly because the drug's larger molecules do not enter cells [11].…”

Section: Resultsmentioning

confidence: 99%

Neuromuscular Blocking Agents and Cancer: A Narrative Review

Chen,

Sun,

et al. 2023

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

Objective. Neuromuscular blocking agents (NMBAs) are part of the three elements of general anaesthesia (sedation, analgesia, and muscle relaxation), which can relax muscles and facilitate intubation and surgery. It has been reported that cancer cells are prone to invasion or metastasis during surgery, but various anaesthetics are currently used in cancer resection, particularly NMBA, and the effects on cancer cell behavior are poorly understood. Guidelines for the correct application of NMBA in cancer surgery have not been reported; therefore, the aim of this paper is to explore the relationship between NMBA and cancer. Methods. Two investigators independently searched PubMed, Embase, the Cochrane Library, Web of Science, and CBM for articles of NMBA and cancer. Results. The available evidence suggests that cisatracurium may be more appropriate for use in anaesthesia for cancer surgery, while rocuronium deserves further attention, particularly for breast and gastric cancer surgery, and vecuronium is suitable for breast cancer and non-small-cell lung cancer, while it is used with caution in gastric cancer. Also, the relationship between NMBA (mivacurium, succinylcholine, gantacurium, and decamethonium bromide) and cancer is unclear and deserves further study. Conclusion. The effect of different NMBAs on cancer cells varies, and the effect of some NMBAs on cancer cells is unclear, and most of the current findings are only from in vitro studies, which need to be validated by further clinical studies in the future to better guide the clinical application of NMBAs.

show abstract

“…A combination of rocuronium and propofol can provide excellent intubating conditions, reducing the discomfort of propofol administration. Combining opioids with rocuronium is also beneficial for intubation conditions and attenuates pain during administration ( Costa, Mourão & Vale, 2022 ). Moreover, the individual antitumor effects of propofol, sufentanil, and rocuronium make them potential candidates for combination therapy in the surgical management of lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Optimization of a tri-drug treatment against lung cancer using orthogonal design in preclinical studies

Tan

Wang

Song

et al. 2023

PeerJ

View full text Add to dashboard Cite

A growing body of evidence suggests that anesthetics impact the outcome of patients with cancer after surgical intervention. However, the optimal dose and underlying mechanisms of co-administered anesthetics in lung tumor therapy have been poorly studied. Here, we aimed to investigate the role of combined anesthetics propofol, sufentanil, and rocuronium in treating lung cancer using an orthogonal experimental design and to explore the optimal combination of anesthetics. First, we evaluated the effects of the three anesthetics on the proliferation and invasion of A-549 cells using Cell Counting Kit 8 and Transwell migration and invasion assays. Subsequently, we applied the orthogonal experimental design (OED) method to screen the appropriate concentrations of the combined anesthetics with the most effective antitumor activity. We found that all three agents inhibited the proliferation of A-549 cells in a dose- and time-dependent manner when applied individually or in combination, with the highest differences in the magnitude of inhibition occurring 24 h after combined drug exposure. The optimal combination of the three anesthetics that achieved the strongest reduction in cell viability was 1.4 µmol/L propofol, 2 nmol/L sufentanil, and 7.83 µmol/L rocuronium. This optimal 3-drug combination produced a more beneficial result at 24 h than either single drug. Our results provide a theoretical basis for improving the efficacy of lung tumor treatment and optimizing anesthetic strategies.

show abstract

Personalized Medicine for Classical Anesthesia Drugs and Cancer Progression

Cited by 4 publications

References 70 publications

The Mechanism of Scopolamine’s Effect on Migration Function of Lung Cancer Cells: A Network Pharmacology and Bioinformatics Perspective

The Mechanism of Scopolamine’s Effect on Migration Function of Lung Cancer Cells: A Network Pharmacology and Bioinformatics Perspective

Neuromuscular Blocking Agents and Cancer: A Narrative Review

Optimization of a tri-drug treatment against lung cancer using orthogonal design in preclinical studies

Contact Info

Product

Resources

About